Advertisement

Neurodegenerative Diseases: Parkinson Disease

  • Serge Weis
  • Michael Sonnberger
  • Andreas Dunzinger
  • Eva Voglmayr
  • Martin Aichholzer
  • Raimund Kleiser
  • Peter Strasser
Chapter
  • 445 Downloads

Abstract

Parkinson disease (PD) is clinically characterized by tremor, bradykinesia, rigidity, postural instability, and gait disturbance. Non-motor features of PD include pain and sensory phenomena, anxiety and depression, autonomic dysfunction, cognitive impairment, dementia, and psychosis and hallucinations.

In neuroradiology, a decreased volume or disappearance of pars compacta of substantia nigra is noted; hypointensities of putamen, substantia nigra, and caudate nucleus are possible (as caused by iron accumulation). A presynaptic dopamine transporter deficit with SPECT tracers like FP-CIT or β-CIT is evident upon nuclear medicine examination.

At the light-microscopic level, loss of neurons in the substantia nigra and locus coeruleus, deposition of melanin pigment in the neuropil or macrophages, and surviving neurons with intracytoplasmatic Lewy bodies are the hallmark of the disease.

Lewy bodies are eosinophilic structures with a dense core and a concentric lamellar structure which stain positive for α-synuclein; thus, PD is an α-synucleinopathy. Six stages in the evolution of PD-related pathology are defined.

Pathogenetic mechanisms at work include oxidative stress, reactive species production, mitochondrial dysfunction, excitotoxicity, increased intracellular free calcium, protein aggregation, ubiquitination of proteins, and inflammation. Confirmed causative genes in PD (autosomal dominant, and autosomal recessive) are named PARK1 until PARK19 which contain missense mutations that alter the protein sequence, duplications, and triplications. The most replicated PD risk loci are SNCA, LRRK2, MAPT, and GBA. Epigenetic mechanisms are involved which alter DNA methylation, histone modification, and non-coding RNAs.

Treatment includes medical therapies (with Levodopa, anticholinergics, amantadine, dopamine receptor agonists, catechol-O-methyltransferase (COMT) inhibition, and monoaminooxidase type B (MAO-B) inhibitors) as well as surgical therapies (deep brain stimulation, lesional surgery). Clinical outcome displays a slow progression of symptoms over several years, an average disease duration of 9–15 years. Side effects from medication include motor fluctuations and dyskinesias.

Selected References

  1. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29(4):454–462.  https://doi.org/10.1002/mds.25844Google Scholar
  2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211Google Scholar
  3. Brooks DJ (2010a) Imaging approaches to Parkinson disease. J Nucl Med 51(4):596–609.  https://doi.org/10.2967/jnumed.108.059998Google Scholar
  4. Brooks DJ (2010b) Imaging dopamine transporters in Parkinson’s disease. Biomark Med 4(5):651–660.  https://doi.org/10.2217/bmm.10.86Google Scholar
  5. Ciurleo R, Di Lorenzo G, Bramanti P (2014) Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson’s disease? Biomed Res Int 2014:519816.  https://doi.org/10.1155/2014/519816Google Scholar
  6. De Rosa P, Marini ES, Gelmetti V, Valente EM (2015) Candidate genes for Parkinson disease: Lessons from pathogenesis. Clin Chim Acta 449:68–76.  https://doi.org/10.1016/j.cca.2015.04.042Google Scholar
  7. van der Merwe C, Jalali Sefid Dashti Z, Christoffels A, Loos B, Bardien S (2015) Evidence for a common biological pathway linking three Parkinson’s disease-causing genes: parkin, PINK1 and DJ-1. Eur J Neurosci 41(9):1113–1125.  https://doi.org/10.1111/ejn.12872. Epub 2015 Mar 11Google Scholar
  8. Dorszewska J, Kozubski W (2016) Introductory chapter – genetic and biochemical factors in Parkinson’s disease. In: Dorszewska J, Kozubski W (eds) Challenges in Parkinson’s disease. InTech, Rijeka, pp 1–6.  https://doi.org/10.5772/64216Google Scholar
  9. Feng Y, Jankovic J, Wu YC (2015) Epigenetic mechanisms in Parkinson’s disease. J Neurol Sci 349(1–2):3–9.  https://doi.org/10.1016/j.jns.2014.1012.1017. Epub 2014 Dec 18Google Scholar
  10. Ferreira M, Massano J (2017) An updated review of Parkinson’s disease genetics and clinicopathological correlations. Acta Neurol Scand 135(3):273–284.  https://doi.org/10.1111/ane.12616. Epub 2016 June 8Google Scholar
  11. Galvan A, Wichmann T (2008) Pathophysiology of parkinsonism. Clin Neurophysiol 119(7):1459–1474.  https://doi.org/10.1016/j.clinph.2008.03.017Google Scholar
  12. Giannoccaro MP, La Morgia C, Rizzo G, Carelli V (2017) Mitochondrial DNA and primary mitochondrial dysfunction in Parkinson’s disease. Mov Disord 32(3):346–363.  https://doi.org/10.1002/mds.26966. Epub 2017 Mar 2Google Scholar
  13. Hernandez DG, Reed X, Singleton AB (2016) Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J Neurochem 139(Suppl 1):59–74.  https://doi.org/10.1111/jnc.13593. Epub 2016 Apr 18Google Scholar
  14. Holtbernd F, Eidelberg D (2014) The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes. Semin Neurol 34(2):202–209.  https://doi.org/10.1055/s-0034-1381733Google Scholar
  15. Kalia LV, Lang AE (2015) Parkinson’s disease. Lancet 386(9996):896–912.  https://doi.org/10.1016/S0140-6736(1014)61393-3. Epub 2015 Apr 19Google Scholar
  16. Kalinderi K, Bostantjopoulou S, Fidani L (2016) The genetic background of Parkinson’s disease: current progress and future prospects. Acta Neurol Scand 12(10):12563Google Scholar
  17. La Cognata V, D’Agata V, Cavalcanti F, Cavallaro S (2016) Genetics of Parkinson’s disease: the role of copy number variations. In: Dorszewska J, Kozubski W (eds) Challenges in Parkinson’s disease. InTech, Rijeka, pp 7–38.  https://doi.org/10.5772/62881Google Scholar
  18. Labbe C, Lorenzo-Betancor O, Ross OA (2016) Epigenetic regulation in Parkinson’s disease. Acta Neuropathol 132(4):515–530.  https://doi.org/10.1007/s00401-016-1590-9. Epub 2016 June 29Google Scholar
  19. Lill CM (2016) Genetics of Parkinson’s disease. Mol Cell Probes 30(6):386–396.  https://doi.org/10.1016/j.mcp.2016.11.001. Epub 2016 Nov 4Google Scholar
  20. Michel PP, Hirsch EC, Hunot S (2016) Understanding dopaminergic cell death pathways in Parkinson disease. Neuron 90(4):675–691.  https://doi.org/10.1016/j.neuron.2016.03.038Google Scholar
  21. Moore K, McKnight AJ, Craig D, O’Neill F (2014) Epigenome-wide association study for Parkinson’s disease. Neuromolecular Med 16(4):845–855.  https://doi.org/10.1007/s12017-014-8332-8. Epub 2014 Oct 11Google Scholar
  22. Obeso JA, Stamelou M (2017) Past, present, and future of Parkinson’s disease: a special essay on the 200th anniversary of the Shaking Palsy. Mov Disord 32(9):1264–1310.  https://doi.org/10.1002/mds.27115Google Scholar
  23. Oertel W, Schulz JB (2016) Current and experimental treatments of Parkinson disease: a guide for neuroscientists. J Neurochem.  https://doi.org/10.1111/jnc.13750
  24. Pihlstrom L, Morset KR, Grimstad E, Vitelli V, Toft M (2016) A cumulative genetic risk score predicts progression in Parkinson’s disease. Mov Disord 8(10):26505Google Scholar
  25. Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12(11):622–634.  https://doi.org/10.1038/nrneurol.2016.152Google Scholar
  26. Rizzo G, Martinelli P, Manners D, Scaglione C, Tonon C, Cortelli P, Malucelli E, Capellari S, Testa C, Parchi P, Montagna P, Barbiroli B, Lodi R (2008) Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson’s disease. Brain 131(Pt 10):2690–2700.  https://doi.org/10.1093/brain/awn195Google Scholar
  27. Savoiardo M (2003) Differential diagnosis of Parkinson’s disease and atypical parkinsonian disorders by magnetic resonance imaging. Neurol Sci 24(Suppl 1):S35–S37.  https://doi.org/10.1007/s100720300036Google Scholar
  28. Trinh J, Farrer M (2013) Advances in the genetics of Parkinson disease. Nat Rev Neurol 9(8):445–454.  https://doi.org/10.1038/nrneurol.2013.132. Epub 2013 July 16Google Scholar
  29. Truban D, Hou X, Caulfield TR, Fiesel FC, Springer W (2017) PINK1, parkin, and mitochondrial quality control: what can we learn about Parkinson’s disease pathobiology? J Park Dis 7(1):13–29.  https://doi.org/10.3233/JPD-160989Google Scholar
  30. Wallis LI, Paley MN, Graham JM, Grunewald RA, Wignall EL, Joy HM, Griffiths PD (2008) MRI assessment of basal ganglia iron deposition in Parkinson’s disease. J Magn Reson Imaging 28(5):1061–1067.  https://doi.org/10.1002/jmri.21563Google Scholar
  31. Zhang H, Duan C, Yang H (2015) Defective autophagy in Parkinson’s disease: lessons from genetics. Mol Neurobiol 51(1):89–104.  https://doi.org/10.1007/s12035-014-8787-5. Epub 2014 July 4Google Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2019

Authors and Affiliations

  • Serge Weis
    • 1
  • Michael Sonnberger
    • 2
  • Andreas Dunzinger
    • 3
  • Eva Voglmayr
    • 2
  • Martin Aichholzer
    • 4
  • Raimund Kleiser
    • 2
  • Peter Strasser
    • 5
  1. 1.Division of Neuropathology, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  2. 2.Department of Neuroradiology, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  3. 3.Department of Neuro-Nuclear Medicine, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  4. 4.Department of Neurosurgery, Neuromed CampusKepler University Hospital, Johannes Kepler UniversityLinzAustria
  5. 5.PMU University Institute for Medical & Chemical Laboratory DiagnosticsSalzburgAustria

Personalised recommendations